Sorafenib inhibits ABCG2 and overcomes irinotecan resistance--response

Affiliations

Comment

Céline Gongora. Mol Cancer Ther. 2014 Mar.

. 2014 Mar;13(3):764.

doi: 10.1158/1535-7163.MCT-13-1026.

¹ Corresponding Author: Céline Gongora, IRCM INSERM U896, 208, rue des Apothicaires, 34298 Montpellier, France. celine.gongora@inserm.fr.

No abstract available

Comment on

Sorafenib overcomes irinotecan resistance in colorectal cancer by inhibiting the ABCG2 drug-efflux pump.
Mazard T, Causse A, Simony J, Leconet W, Vezzio-Vie N, Torro A, Jarlier M, Evrard A, Del Rio M, Assenat E, Martineau P, Ychou M, Robert B, Gongora C. Mazard T, et al. Mol Cancer Ther. 2013 Oct;12(10):2121-34. doi: 10.1158/1535-7163.MCT-12-0966. Epub 2013 Aug 19. Mol Cancer Ther. 2013. PMID: 23960095
Sorafenib inhibits ABCG2 and overcomes irinotecan resistance--letter.
Smith MA. Smith MA. Mol Cancer Ther. 2014 Mar;13(3):763. doi: 10.1158/1535-7163.MCT-13-0968. Mol Cancer Ther. 2014. PMID: 24615774 Free PMC article. No abstract available.